Pancreatic fistula medical therapy: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Pancreatic_fistula}} {{CMG}} ==Overview== ==Medical Therapy== The production of pancreatic enzymes is suppressed by restricting the patient's oral intake of food..." |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Treatment of [[pancreatic]] [[fistula]] includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications. [[Medical]] [[therapy]] is tailored towards the suppression of [[pancreatic]] [[enzymes]] by restricting the patient's oral intake of food in conjunction with the use of long-acting [[somatostatin]] analogues such as [[octreotide]]. Correction of the fluid and [[electrolyte]] abnormalities. The patient's nutrition is maintained by [[total parenteral nutrition]]. This treatment is continued for 2-3 weeks, and the patient is observed for improvement. | |||
==Medical Therapy== | |||
Treatment of [[pancreatic]] [[fistula]] includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications. | |||
* [[Medical]] [[therapy]] is tailored towards the suppression of [[pancreatic]] [[enzymes]] by restricting the patient's oral intake of food in conjunction with the use of long-acting [[somatostatin]] analogues such as [[octreotide]].<ref>{{cite journal | author=Takeo C, Myojo S | title=Marked effect of octreotide acetate in a case of pancreatic pleural effusion | journal=Curr Med Res Opin | year=2000 | pages=171-7 | volume=16 | issue=3 | id=PMID 11191006}}</ref> [[Octreotide]] is used commonly to control [[pancreatic]] secretion, however, no significant benefit is observed with its use in patients with already established [[pancreatic]] [[fistula]].<ref name="pmid32809706">{{cite journal| author=| title=StatPearls | journal= | year= 2021 | volume= | issue= | pages= | pmid=32809706 | doi= | pmc= | url= }} </ref> | |||
* Correction of the [[electrolyte disturbances]]. | |||
This treatment is continued for 2-3 weeks, and the patient is observed for improvement. | * The patient's nutrition is maintained by [[total parenteral nutrition]] to reduce [[pancreatic]] stimulation. This treatment is continued for 2-3 weeks, and the patient is observed for improvement.<ref name="pmid29588609">{{cite journal| author=Nahm CB, Connor SJ, Samra JS, Mittal A| title=Postoperative pancreatic fistula: a review of traditional and emerging concepts. | journal=Clin Exp Gastroenterol | year= 2018 | volume= 11 | issue= | pages= 105-118 | pmid=29588609 | doi=10.2147/CEG.S120217 | pmc=5858541 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29588609 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 19:45, 5 April 2021
|
Pancreatic fistula Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pancreatic fistula medical therapy On the Web |
|
American Roentgen Ray Society Images of Pancreatic fistula medical therapy |
|
Risk calculators and risk factors for Pancreatic fistula medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Treatment of pancreatic fistula includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications. Medical therapy is tailored towards the suppression of pancreatic enzymes by restricting the patient's oral intake of food in conjunction with the use of long-acting somatostatin analogues such as octreotide. Correction of the fluid and electrolyte abnormalities. The patient's nutrition is maintained by total parenteral nutrition. This treatment is continued for 2-3 weeks, and the patient is observed for improvement.
Medical Therapy
Treatment of pancreatic fistula includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications.
- Medical therapy is tailored towards the suppression of pancreatic enzymes by restricting the patient's oral intake of food in conjunction with the use of long-acting somatostatin analogues such as octreotide.[1] Octreotide is used commonly to control pancreatic secretion, however, no significant benefit is observed with its use in patients with already established pancreatic fistula.[2]
- Correction of the electrolyte disturbances.
- The patient's nutrition is maintained by total parenteral nutrition to reduce pancreatic stimulation. This treatment is continued for 2-3 weeks, and the patient is observed for improvement.[3]
References
- ↑ Takeo C, Myojo S (2000). "Marked effect of octreotide acetate in a case of pancreatic pleural effusion". Curr Med Res Opin. 16 (3): 171–7. PMID 11191006.
- ↑ "StatPearls". 2021. PMID 32809706 Check
|pmid=value (help). - ↑ Nahm CB, Connor SJ, Samra JS, Mittal A (2018). "Postoperative pancreatic fistula: a review of traditional and emerging concepts". Clin Exp Gastroenterol. 11: 105–118. doi:10.2147/CEG.S120217. PMC 5858541. PMID 29588609.